Last reviewed · How we verify
K-757 and K-833 QD — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
K-757 and K-833 QD (K-757 and K-833 QD) — Kallyope Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| K-757 and K-833 QD TARGET | K-757 and K-833 QD | Kallyope Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- K-757 and K-833 QD CI watch — RSS
- K-757 and K-833 QD CI watch — Atom
- K-757 and K-833 QD CI watch — JSON
- K-757 and K-833 QD alone — RSS
Cite this brief
Drug Landscape (2026). K-757 and K-833 QD — Competitive Intelligence Brief. https://druglandscape.com/ci/k-757-and-k-833-qd. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab